Sequent Scientific receives WHO prequalification approval for Albendazole API

19 Aug 2024 Evaluate

Sequent Scientific has received prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro’s Chewable formulation is the first global approval of its kind by the WHO PQ. 

Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middleincome countries. The WHO prequalification recognizes Sequent Scientific’s commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality. 

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. 


Sequent Scientific Share Price

151.95 5.30 (3.61%)
05-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1581.95
Dr. Reddys Lab 1126.55
Cipla 1418.45
Lupin 2009.65
Zydus Lifesciences 887.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...